Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

Liquid Biopsies.

Lianidou E, Pantel K.

Genes Chromosomes Cancer. 2018 Nov 1. doi: 10.1002/gcc.22695. [Epub ahead of print] Review.

PMID:
30382599
2.

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes.

Soler A, Cayrefourcq L, Mazard T, Babayan A, Lamy PJ, Assou S, Assenat E, Pantel K, Alix-Panabières C.

Sci Rep. 2018 Oct 29;8(1):15931. doi: 10.1038/s41598-018-34365-z.

3.

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group.

J Natl Cancer Inst. 2018 Oct 11. doi: 10.1093/jnci/djy152. [Epub ahead of print]

PMID:
30312434
4.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H.

BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.

5.

ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer.

Nastały P, Filipska M, Morrissey C, Eltze E, Semjonow A, Brandt B, Pantel K, Bednarz-Knoll N.

Transl Res. 2018 Sep 12. pii: S1931-5244(18)30142-7. doi: 10.1016/j.trsl.2018.08.007. [Epub ahead of print]

PMID:
30287243
6.

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.

Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A.

Breast Cancer Res Treat. 2018 Oct 1. doi: 10.1007/s10549-018-4972-y. [Epub ahead of print]

PMID:
30276763
7.

Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer.

Woestemeier A, Ghadban T, Riethdorf S, Harms-Effenberger K, Konczalla L, Uzunoglu FG, Izbicki JR, Pantel K, Bockhorn M, Reeh M.

Anticancer Res. 2018 Oct;38(10):5665-5669. doi: 10.21873/anticanres.12902.

PMID:
30275185
8.

Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.

Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.

Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31905. [Epub ahead of print]

PMID:
30265376
9.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.

J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33041-7. doi: 10.1016/j.jtho.2018.08.2025. [Epub ahead of print] No abstract available.

PMID:
30205165
10.

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.

Ni Q, Stevic I, Pan C, Müller V, Oliviera-Ferrer L, Pantel K, Schwarzenbach H.

Sci Rep. 2018 Aug 28;8(1):12974. doi: 10.1038/s41598-018-31108-y.

11.

Exosomal microRNAs as tumor markers in epithelial ovarian cancer.

Pan C, Stevic I, Müller V, Ni Q, Oliveira-Ferrer L, Pantel K, Schwarzenbach H.

Mol Oncol. 2018 Nov;12(11):1935-1948. doi: 10.1002/1878-0261.12371. Epub 2018 Oct 9.

12.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer.

Schiewek J, Schumacher U, Lange T, Joosse SA, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.

PMID:
30094535
13.

miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes.

Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier CH, Bachelier R, Allioli N, Hong SS, Bartkowiak K, Pantel K, Clézardin P.

Cancer Res. 2018 Sep 15;78(18):5259-5273. doi: 10.1158/0008-5472.CAN-17-3058. Epub 2018 Jul 24.

PMID:
30042152
14.

Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients.

Joosse SA, Souche FR, Babayan A, Gasch C, Kerkhoven RM, Ramos J, Fabre JM, Riethdorf S, König A, Wikman H, Alix-Panabières C, Pantel K.

Clin Chem. 2018 Oct;64(10):1505-1512. doi: 10.1373/clinchem.2018.289819. Epub 2018 Jul 20.

PMID:
30030273
15.

Abstracts from the 11th International Symposium on Minimal Residual Disease, 3-5 May 2018, Montpellier, France.

Alix-Panabières C, Pantel K.

Clin Exp Metastasis. 2018 Jul 14. doi: 10.1007/s10585-018-9911-0. [Epub ahead of print] No abstract available.

PMID:
30008067
16.

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer EF, Fehm T, Müller V.

Breast Cancer Res Treat. 2018 Jul 12. doi: 10.1007/s10549-018-4882-z. [Epub ahead of print]

PMID:
30003393
17.

11th International Symposium on Minimal Residual Cancer (ISMRC): 3-5 May 2018, Montpellier, France.

Alix-Panabières C, Pantel K.

Clin Exp Metastasis. 2018 Mar;35(3):87-90. doi: 10.1007/s10585-018-9909-7. Epub 2018 Jul 6. No abstract available.

PMID:
29980892
18.

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.

Bauer ECA, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl TWP, Fasching PA, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Janni W, Rack B, Scholz C; SUCCESS Study Group.

Breast Cancer Res Treat. 2018 Jun 21. doi: 10.1007/s10549-018-4856-1. [Epub ahead of print]

PMID:
29931425
19.

Inverse Perfusion Requirements of Supra- and Infratentorial Brain Metastases Formation.

Schneider T, Kemmling A, Schroeder J, Pantel K, Glatzel M, Schoen G, Mohme M, Fiehler J, Gellißen S.

Front Neurol. 2018 May 30;9:391. doi: 10.3389/fneur.2018.00391. eCollection 2018.

20.

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY.

Ann Oncol. 2018 Aug 1;29(8):1777-1783. doi: 10.1093/annonc/mdy211.

PMID:
29893791
21.

Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases.

Le UT, Bronsert P, Picardo F, Riethdorf S, Haager B, Rylski B, Czerny M, Beyersdorf F, Wiesemann S, Pantel K, Passlick B, Kaifi JT, Schmid S.

Sci Rep. 2018 Jun 8;8(1):8751. doi: 10.1038/s41598-018-26410-8.

22.

Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy."

Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M.

Urol Oncol. 2018 Jul;36(7):347-348. doi: 10.1016/j.urolonc.2018.05.013. Epub 2018 Jun 5.

PMID:
29880457
23.

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization.

Chen S, El-Heliebi A, Schmid J, Kashofer K, Czyż ZT, Polzer BM, Pantel K, Kroneis T, Sedlmayr P.

J Vis Exp. 2018 May 15;(135). doi: 10.3791/56394.

24.

Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases.

Gerstenberger W, Wrage M, Kettunen E, Pantel K, Anttila S, Steurer S, Wikman H.

Anal Cell Pathol (Amst). 2018 Apr 10;2018:8651790. doi: 10.1155/2018/8651790. eCollection 2018.

25.

Clinical utility of circulating non-coding RNAs - an update.

Anfossi S, Babayan A, Pantel K, Calin GA.

Nat Rev Clin Oncol. 2018 Sep;15(9):541-563. doi: 10.1038/s41571-018-0035-x. Review.

PMID:
29784926
26.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching PA, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer EF, Witzel I, Müller V.

BMC Cancer. 2018 May 8;18(1):541. doi: 10.1186/s12885-018-4282-0.

27.

Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy.

Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner JM, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S.

Cancer Res. 2018 Jun 15;78(12):3220-3232. doi: 10.1158/0008-5472.CAN-17-3415. Epub 2018 Apr 19.

PMID:
29674477
28.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
29.

Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells.

Follain G, Osmani N, Azevedo AS, Allio G, Mercier L, Karreman MA, Solecki G, Garcia Leòn MJ, Lefebvre O, Fekonja N, Hille C, Chabannes V, Dollé G, Metivet T, Hovsepian F, Prudhomme C, Pichot A, Paul N, Carapito R, Bahram S, Ruthensteiner B, Kemmling A, Siemonsen S, Schneider T, Fiehler J, Glatzel M, Winkler F, Schwab Y, Pantel K, Harlepp S, Goetz JG.

Dev Cell. 2018 Apr 9;45(1):33-52.e12. doi: 10.1016/j.devcel.2018.02.015.

PMID:
29634935
30.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells.

Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S.

Haematologica. 2018 Jun;103(6):939-948. doi: 10.3324/haematol.2017.181354. Epub 2018 Mar 22.

31.

Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer.

Effenberger KE, Schroeder C, Hanssen A, Wolter S, Eulenburg C, Tachezy M, Gebauer F, Izbicki JR, Pantel K, Bockhorn M.

Clin Cancer Res. 2018 Jun 15;24(12):2844-2850. doi: 10.1158/1078-0432.CCR-18-0120. Epub 2018 Mar 20.

PMID:
29559560
32.

Advances in liquid biopsy approaches for early detection and monitoring of cancer.

Babayan A, Pantel K.

Genome Med. 2018 Mar 20;10(1):21. doi: 10.1186/s13073-018-0533-6.

33.

Prostate cancer: Circulating tumour cells in prostate cancer.

Hille C, Pantel K.

Nat Rev Urol. 2018 May;15(5):265-266. doi: 10.1038/nrurol.2018.25. Epub 2018 Mar 6. No abstract available.

PMID:
29508846
34.

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.

Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, Schneeweiss A, Müller V, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Fehm T, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann MW, Fasching PA, Janni W, Friedl TWP; SUCCESS Study Group.

Oncol Res Treat. 2018;41(3):93-98. doi: 10.1159/000485566. Epub 2018 Feb 27.

PMID:
29490302
35.

Clinical applications of the CellSearch platform in cancer patients.

Riethdorf S, O'Flaherty L, Hille C, Pantel K.

Adv Drug Deliv Rev. 2018 Feb 1;125:102-121. doi: 10.1016/j.addr.2018.01.011. Epub 2018 Feb 2. Review.

PMID:
29355669
36.

Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.

Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Burwinkel B.

Breast Cancer Res Treat. 2018 May;169(1):69-82. doi: 10.1007/s10549-018-4666-5. Epub 2018 Jan 16.

PMID:
29340881
37.

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells.

El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges TM, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P.

Clin Chem. 2018 Mar;64(3):536-546. doi: 10.1373/clinchem.2017.281295. Epub 2018 Jan 4.

PMID:
29301749
38.

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.

Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun HT, Coxon A, Lee B, Kang Y.

Cancer Cell. 2017 Dec 11;32(6):731-747.e6. doi: 10.1016/j.ccell.2017.11.002.

PMID:
29232552
39.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Sci Rep. 2017 Dec 11;7(1):17307. doi: 10.1038/s41598-017-17514-8.

40.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection.

von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse AW, Riethdorf S, Wege H.

Oncotarget. 2017 Sep 23;8(52):89978-89987. doi: 10.18632/oncotarget.21208. eCollection 2017 Oct 27.

41.

Disseminated breast tumour cells: biological and clinical meaning.

Pantel K, Hayes DF.

Nat Rev Clin Oncol. 2018 Mar;15(3):129-131. doi: 10.1038/nrclinonc.2017.174. Epub 2017 Nov 21. No abstract available.

PMID:
29158590
42.

Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.

Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, Kuske A, Gorges TM, Joosse SA, Kroneis T, Zabel M, Sedlmayr P, Alix-Panabières C, Pantel K, Lianidou ES.

Clin Chem. 2018 Feb;64(2):297-306. doi: 10.1373/clinchem.2017.275503. Epub 2017 Nov 9.

PMID:
29122836
43.

[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].

Gschwend JE, Albers P, Bögemann M, Goebell P, Heidenreich A, Klier J, König F, Machtens S, Pantel K, Thomas C.

Urologe A. 2018 Jan;57(1):34-39. doi: 10.1007/s00120-017-0533-y. German.

PMID:
29071398
44.

Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.

Bailey DL, Pichler BJ, Gückel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, Krackhardt AM, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L, Beyer T.

Mol Imaging Biol. 2018 Feb;20(1):4-20. doi: 10.1007/s11307-017-1123-5. Review.

45.

Detection of Circulating Plasma Cells in Multiple Myeloma.

Alix-Panabières C, Pantel K.

Clin Chem. 2017 Dec;63(12):1797-1798. doi: 10.1373/clinchem.2017.275446. Epub 2017 Sep 18. No abstract available.

PMID:
28923846
46.

Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study.

Soave A, Chun FK, Hillebrand T, Rink M, Weisbach L, Steinbach B, Fisch M, Pantel K, Schwarzenbach H.

Oncotarget. 2017 May 7;8(34):56398-56407. doi: 10.18632/oncotarget.17657. eCollection 2017 Aug 22.

47.

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

O'Flaherty L, Wikman H, Pantel K.

Transl Lung Cancer Res. 2017 Aug;6(4):431-443. doi: 10.21037/tlcr.2017.07.03. Review.

48.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.

Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S.

Nat Commun. 2017 Aug 16;8(1):269. doi: 10.1038/s41467-017-00327-8.

49.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases.

Mohme M, Riethdorf S, Dreimann M, Werner S, Maire CL, Joosse SA, Bludau F, Mueller V, Neves RPL, Stoecklein NH, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker SO.

Sci Rep. 2017 Aug 3;7(1):7196. doi: 10.1038/s41598-017-07649-z.

50.

Biological labels: Here comes the spaser.

Alix-Panabières C, Pantel K.

Nat Mater. 2017 Jul 26;16(8):790-791. doi: 10.1038/nmat4943. No abstract available.

PMID:
28748959

Supplemental Content

Loading ...
Support Center